Nanog Increases Focal Adhesion Kinase (FAK) Promoter Activity and Expression and Directly Binds to FAK Protein to Be Phosphorylated

Por Ho, Baotran, Olson, Gretchen, Figel, Sheila, Gelman, Irwin, Cance, William G., Golubovskaya, Vita M.
Publicado em 2012

Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-kinase Inhibitors

Por Marlowe, Timothy A., Lenzo, Felicia L., Figel, Sheila A., Grapes, Abigail T., Cance, William G.
Publicado no Mol Cancer Ther (2016)

Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination

Por Galbo, Phillip M., Ciesielski, Michael J., Figel, Sheila, Maguire, Orla, Qiu, Jingxin, Wiltsie, Laura, Minderman, Hans, Fenstermaker, Robert A.
Publicado no Oncotarget (2017)

Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth in vivo

Por Fenstermaker, Robert A., Figel, Sheila A., Qiu, Jingxin, Barone, Tara A., Dharma, Sanam S., Winograd, Evan K., Galbo, Phillip M., Wiltsie, Laura M., Ciesielski, Michael J.
Publicado no Clin Cancer Res (2018)

A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits...

Por Golubovskaya, Vita M., Figel, Sheila, Ho, Baotran T., Johnson, Christopher P., Yemma, Michael, Huang, Grace, Zheng, Min, Nyberg, Carl, Magis, Andrew, Ostrov, David A., Gelman, Irwin H., Cance, William G.
Publicado em 2012